Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

Richard S Roden, William H. Yutzy IV, Rosemary Fallon, Stephen Inglis, Douglas R. Lowy, John T. Schiller

Research output: Contribution to journalArticle

Abstract

Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human papillomavirus (HPV) genital types 6, 16, and 18, induces predominantly type-specific neutralizing antibodies. L2 polypeptide vaccines protect animals against experimental challenge with homologous papillomavirus and cross-reactive epitopes are present in HPV L2. To assess L2-specific cross-neutralization of HPV genotypes, sheep were immunized with purified, bacterially expressed HPV6, 16, or 18 L2. In addition to neutralizing the homologous HPV type in vitro, antisera to each HPV L2 also cross-neutralized both heterologous HPV types. This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)254-257
Number of pages4
JournalVirology
Volume270
Issue number2
DOIs
StatePublished - May 10 2000

Fingerprint

Capsid Proteins
Epitopes
Virion
Vaccines
Human papillomavirus 6
Papillomavirus Vaccines
Peptides
Neutralizing Antibodies
Immune Sera
Sheep
Vaccination
Genotype

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. / Roden, Richard S; Yutzy IV, William H.; Fallon, Rosemary; Inglis, Stephen; Lowy, Douglas R.; Schiller, John T.

In: Virology, Vol. 270, No. 2, 10.05.2000, p. 254-257.

Research output: Contribution to journalArticle

Roden, Richard S ; Yutzy IV, William H. ; Fallon, Rosemary ; Inglis, Stephen ; Lowy, Douglas R. ; Schiller, John T. / Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. In: Virology. 2000 ; Vol. 270, No. 2. pp. 254-257.
@article{1b7090c0bcf04b7fbc049a12330d1ed3,
title = "Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes",
abstract = "Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human papillomavirus (HPV) genital types 6, 16, and 18, induces predominantly type-specific neutralizing antibodies. L2 polypeptide vaccines protect animals against experimental challenge with homologous papillomavirus and cross-reactive epitopes are present in HPV L2. To assess L2-specific cross-neutralization of HPV genotypes, sheep were immunized with purified, bacterially expressed HPV6, 16, or 18 L2. In addition to neutralizing the homologous HPV type in vitro, antisera to each HPV L2 also cross-neutralized both heterologous HPV types. This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection. (C) 2000 Academic Press.",
author = "Roden, {Richard S} and {Yutzy IV}, {William H.} and Rosemary Fallon and Stephen Inglis and Lowy, {Douglas R.} and Schiller, {John T.}",
year = "2000",
month = "5",
day = "10",
doi = "10.1006/viro.2000.0272",
language = "English (US)",
volume = "270",
pages = "254--257",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes

AU - Roden, Richard S

AU - Yutzy IV, William H.

AU - Fallon, Rosemary

AU - Inglis, Stephen

AU - Lowy, Douglas R.

AU - Schiller, John T.

PY - 2000/5/10

Y1 - 2000/5/10

N2 - Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human papillomavirus (HPV) genital types 6, 16, and 18, induces predominantly type-specific neutralizing antibodies. L2 polypeptide vaccines protect animals against experimental challenge with homologous papillomavirus and cross-reactive epitopes are present in HPV L2. To assess L2-specific cross-neutralization of HPV genotypes, sheep were immunized with purified, bacterially expressed HPV6, 16, or 18 L2. In addition to neutralizing the homologous HPV type in vitro, antisera to each HPV L2 also cross-neutralized both heterologous HPV types. This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection. (C) 2000 Academic Press.

AB - Vaccination with virus-like particles (VLP), comprising both L1 and L2 of human papillomavirus (HPV) genital types 6, 16, and 18, induces predominantly type-specific neutralizing antibodies. L2 polypeptide vaccines protect animals against experimental challenge with homologous papillomavirus and cross-reactive epitopes are present in HPV L2. To assess L2-specific cross-neutralization of HPV genotypes, sheep were immunized with purified, bacterially expressed HPV6, 16, or 18 L2. In addition to neutralizing the homologous HPV type in vitro, antisera to each HPV L2 also cross-neutralized both heterologous HPV types. This suggests that unlike VLP-based prophylactic HPV vaccines, an L2 polypeptide vaccine may provide broad-spectrum protection. (C) 2000 Academic Press.

UR - http://www.scopus.com/inward/record.url?scp=0034630951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034630951&partnerID=8YFLogxK

U2 - 10.1006/viro.2000.0272

DO - 10.1006/viro.2000.0272

M3 - Article

C2 - 10792983

AN - SCOPUS:0034630951

VL - 270

SP - 254

EP - 257

JO - Virology

JF - Virology

SN - 0042-6822

IS - 2

ER -